Phase I studies of vorinostat with ixazomib or pazopanib imply a role of antiangiogenesis-based therapy for TP53 mutant malignancies | Scientific Reports
Vorinostat in single agent trials | Download Table
A trial of vorinostat for advanced mesothelioma | Cancer Research UK
Clinical trials of vorinostat in combination therapy in patients with... | Download Table
Delivery systems for vorinostat in cancer treatment: An updated review - ScienceDirect
Characteristics of HDAC inhibitors in clinical trials. | Download Table
Phase I/II intra-patient dose escalation study of vorinostat in children with relapsed solid tumor, lymphoma, or leukemia | Clinical Epigenetics | Full Text
References in Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study - The Lancet Oncology
Frontiers | Discovery of a Novel Hybrid of Vorinostat and Riluzole as a Potent Antitumor Agent | Cell and Developmental Biology
Adding Vorinostat to Revlimid Post-transplant Maintenance Therapy… – Myeloma Research News
Vorinostat in solid and hematologic malignancies | Journal of Hematology & Oncology | Full Text
Vorinostat and quinacrine have synergistic effects in T-cell acute lymphoblastic leukemia through reactive oxygen species increase and mitophagy inhibition | Cell Death & Disease
Vorinostat in published phase II clinical trials in solid tumors. | Download Table
Table 1 from Epi-drugs to fight cancer: from chemistry to cancer treatment, the road ahead. | Semantic Scholar
Vorinostat - Wikipedia
Frontiers | Combination Therapy With Histone Deacetylase Inhibitors (HDACi) for the Treatment of Cancer: Achieving the Full Therapeutic Potential of HDACi | Oncology
Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker | British Journal of Cancer
Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug | Nature Biotechnology
Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial - The Lancet Oncology
Vorinostat-induced autophagy switches from a death-promoting to a cytoprotective signal to drive acquired resistance | Cell Death & Disease
Vorinostat (SAHA) in clinical trials (N/A-not analyzed). | Download Scientific Diagram
IJMS | Free Full-Text | Targeting Histone Deacetylases to Modulate Graft-Versus-Host Disease and Graft-Versus-Leukemia | HTML
The Mechanism of Action of the Histone Deacetylase Inhibitor Vorinostat Involves Interaction with the Insulin-Like Growth Factor Signaling Pathway
